ReviewFrontiers in pharmacology2024
Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria.
Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Liposome-Mediated Bacterial Ferroptosis-like Death: A Novel Paradigm for Antimicrobial Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Phage-Derived Endolysins TargetingAntibiotics (Basel, Switzerland) · 2026Review
- Helicobacter pylori phages: resource landscape, translational challenges, and engineered antibacterial strategies.Archives of microbiology · 2026Review
- Prophages in Skin Pathogens: From Virulence to Therapy.Pathogens (Basel, Switzerland) · 2026Review
- Polycationic nanopeptide-fused endolysins for the control of Mannheimia haemolytica.Applied microbiology and biotechnology · 2026Article
- Innovative Approaches to Combat Antimicrobial Resistance: A Review of Emerging Therapies and Technologies.Probiotics and antimicrobial proteins · 2026Review
- Physicochemical and Proteolytic Barriers Limiting Activity of Cpl-1 and Pal Endolysins in Human Circulation.Current issues in molecular biology · 2026Article
- Slowpoke: An Automated Golden Gate Cloning Workflow for Opentrons OT-2 and Flex.ACS synthetic biology · 2026Article
- Comparative Combinatorial Effects of Endolysins LNT103 with Ten Conventional Antibiotics against Gram-Negative Bacterial Pathogens.Journal of microbiology and biotechnology · 2026Article
- Nano-Enabled Delivery of Phage-Based Antibacterials Against ESKAPE Pathogens.Pharmaceutics · 2026Review
- Autoimmune disease-associated pathobionts: mechanisms and therapeutic potential of phage-based approaches.Frontiers in immunology · 2026Review
- Characterization and phage-antibiotic synergy of bacteriophages PES-1 and PES-2 against porcine enterotoxigenicFrontiers in microbiology · 2026Article
- In Vitro Assays for Endolysin Efficacy and Safety Profiling.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Prophage landscapes in clinical MRSA: safety profiling and discovery of Lys81, a broad-spectrum bacteriolytic enzyme.Frontiers in microbiology · 2026Article
- Avian PathogenicVeterinary sciences · 2025Review
- Characterization and genome analysis of jumbo Escherichia phage UE-S1 and the antibacterial potential of its lysozyme against uropathogenic E. coli.BMC microbiology · 2025Article
- Second-generation lysocins as therapeutics for treatingAntimicrobial agents and chemotherapy · 2025Article
- Wound-Healing Potential of Engineered Lysin GRC-ML07 inAntibiotics (Basel, Switzerland) · 2025Article
- The C-terminal domain of T9SS component protein SprA assistsApplied and environmental microbiology · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic-resistant bacteria are rapidly emerging, and the increasing prevalence of multidrug-resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.